Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Lots of stars are slimming down, igniting a Hollywood trend that raises concerns about the return of dangerous beauty standards.

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Whoopi Goldberg has stunned in her latest looks showing off her 100+ pound weight loss after taking popular weight loss drug ...

A boost for the category, and perhaps even a change in the way products are marketed, is anticipated based on research ...

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Social media users are claiming berberine, a dietary supplement, to be "nature's Ozempic." Can it be used for weight loss?

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.